| Project/Area Number |
25462283
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurosurgery
|
|---|
| Research Institution | National Cancer Center Japan (2015)
National Center of Neurology and Psychiatry (2013) |
|---|
Principal Investigator |
ICHIMURA Koichi 国立研究開発法人国立がん研究センター, その他部局等, 分野長 (40231146)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
USHIJIMA Toshikazu 国立がん研究センター, エピゲノム解析分野, 分野長 (90232818)
NARITA Yoshitaka 国立がん研究センター, 脳脊髄腫瘍科, 科長 (40392344)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | 脳腫瘍 / 遺伝子変異 / 次世代シークエンス / 膠芽腫 / 分子分類 / TERT / グリオーマ / Ion Torrent / 遺伝子診断 / マイクロアレイ / CGH / IonTorrent |
|---|
| Outline of Final Research Achievements |
Glioblastomas are the most common and malignant brain tumors. For molecular classification of gliomas, we established a series of robust assays to screen IDH mutations, TERT promoter mutations, 1p/19q codeletion and MGMT methylation. Using these assays, a total of 951 adult gliomas including 453 glioblastomas collected through a multi-center collaboration were studied. We found that a molecular classification by a combination of IDH mutation and TERT mutation was strongly associated with prognosis of the glioma patients. In addition, we found that a significant interaction between TERT mutation and MGMT methylation was associated with prognosis of glioblastomas and that the combination of these alterations could serve as a useful prognostic marker. We have also established a Glioma Mutation Screening Panel for 93 genes known to be frequently mutated in gliomas. Using this panel, we are screening glioblastomas for mutations to identify a novel prognostic marker(s).
|
